Pharvaris N.V. (NASDAQ:PHVS) Receives Average Recommendation of “Moderate Buy” from Analysts

Pharvaris N.V. (NASDAQ:PHVS) has been given a consensus recommendation of “Moderate Buy” by the fourteen brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, ten have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $50.0833.

A number of equities research analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a report on Friday, July 17th. UBS Group set a $74.00 price target on Pharvaris in a report on Wednesday, May 13th. Morgan Stanley upped their price objective on Pharvaris from $41.00 to $46.00 and gave the stock an “overweight” rating in a research report on Thursday, June 25th. Citigroup reaffirmed a “buy” rating on shares of Pharvaris in a research note on Wednesday, April 15th. Finally, Wall Street Zen downgraded Pharvaris from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th.

Insider Buying and Selling

In related news, CEO Berndt Modig sold 2,291 shares of Pharvaris stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $31.07, for a total transaction of $71,181.37. Following the sale, the chief executive officer directly owned 135,209 shares of the company’s stock, valued at approximately $4,200,943.63. The trade was a 1.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total transaction of $1,089,968.88. Following the transaction, the director owned 315,167 shares of the company’s stock, valued at approximately $11,185,276.83. This represents a 8.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 178,322 shares of company stock worth $5,969,286 in the last quarter.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new stake in shares of Pharvaris during the 4th quarter valued at $35,000. JPMorgan Chase & Co. increased its holdings in Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares in the last quarter. Barclays PLC acquired a new position in Pharvaris in the 4th quarter worth about $77,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in Pharvaris in the 4th quarter worth about $86,000. Finally, CoreCap Advisors LLC bought a new position in Pharvaris in the second quarter valued at about $93,000.

Pharvaris Stock Performance

Shares of Pharvaris stock opened at $34.91 on Monday. The company has a market cap of $2.28 billion, a PE ratio of -10.98 and a beta of -2.31. The company has a 50 day moving average of $33.24 and a 200-day moving average of $29.85. Pharvaris has a 1-year low of $19.56 and a 1-year high of $36.60.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. Research analysts forecast that Pharvaris will post -2.97 earnings per share for the current year.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.